Pfizer (NYSE:PFE) has handed a large part of its obesity research bill to an outside investor. At 4:30 p.m. ET on November 11, 2026, after the close, Pfizer and Blackstone Life Sciences, the drug-financing arm of Blackstone (NYSE:BX), said Blackstone-managed funds will cover up to $1.5 billion of development costs through 2028 for berobenatide. Berobenatide is Pfizer’s experimental once-monthly GLP-1 injection.

Pfizer retains ownership of berobenatide, all rights to the drug and full control of the program, and its equity stays with existing shareholders. Blackstone collects milestone payments over several years. Those payments are triggered by U.S. approval of monthly berobenatide as a stand-alone weight-management treatment and by certain sales targets. Neither company disclosed its size.

Pfizer closed at $29.45, up 0.31%, in regular trading before the news. It then traded at $29.48 after hours at 7:59 p.m. ET, while Blackstone closed at $122.01, down 0.43%.

What Pfizer Signed and What It Left Out

The commitment is capped, runs through a set deadline, and covers only development costs. Capital from BXPE, Blackstone’s perpetual private equity vehicle (a fund with no fixed end date), will invest alongside the Life Sciences funds, which manage about $18 billion.

The release does not mention royalties, milestone amounts, a yearly draw schedule, or Blackstone’s target return, but Pfizer’s chief financial officer, Cecile Guegan, described the deal as part of a careful approach to bringing new medicines to patients.

Pfizer has used this structure before. Its 2023 deal with Blackstone provided up to $550 million to co-fund development, so the new agreement is a larger version of a known arrangement.

Sizing the Deal for Each Company

For Pfizer, the money supports more than 20 obesity and related trials planned in 2026, including 10 ongoing and planned Phase III studies of berobenatide. Pfizer guided 2026 adjusted R&D spending to $10.8 to $11.8 billion, so the funding eases the strain without changing the size of the company’s research budget. Pfizer gives up some upside in exchange. If berobenatide works, the undisclosed milestones come out of Pfizer’s profits, but if it fails, Blackstone covers much of the development bill.

For Blackstone, the commitment is insignificant against $1.35 trillion in assets under management. What it gains is a return stream tied to drug risk, which does not move with buyouts or real estate, plus a place to put BXPE’s permanent capital.

Where Berobenatide Stands Against Lilly and Novo

Pfizer got berobenatide by buying Metsera for $65.60 a share in cash plus a contingent value right (a payout tied to future milestones) of up to $20.65 a share. It won Metsera after a bidding war with Wegovy maker Novo Nordisk (NYSE:NVO).

In June 2026, Pfizer reported 15.9% average weight loss at 32 weeks on the 2.4 mg weekly dose, not adjusted for placebo. One analyst estimate puts Zepbound from Eli Lilly (NYSE:LLY) at roughly 17% at a similar point, and other analysts called the data solid but undifferentiated.

Monthly dosing is what Pfizer is selling as its edge, but the key monthly data arrive in 2028. Analysts expect a weekly launch first and a monthly maintenance option in 2029.

Weighing Pfizer’s Dividend Against the Obesity Timeline

Pfizer’s investment case rests mainly on income. The $1.72 annual dividend yields 5.82%, management raised 2026 adjusted EPS guidance to $2.95-$3.05, and outside money now carries part of the obesity spending that could have squeezed the payout.

The return is years away, and guidance already accounts for about $1.1 billion in generic and biosimilar pressure. The high yield also reflects a modest valuation of about 22 times earnings.

The shares are up 26.23% this year, between a one-year low of $23.62 and a high of $31.44. Until the obesity data arrive, the dividend provides most of the return for shareholders.

This view is wrong if Pfizer cuts the $1.72 dividend before the 2028 monthly results, and if the stock closes above $31.44, that would signal the market is starting to give the obesity program credit.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.